Sharp Edge Labs announced Monday that the company has been awarded a $156K grant from the National Institutes of Health to develop biosensor technology for measuring the levels of molecules involved in cancer. The Phase 1 SBIR grant will allow the NSIV graduate to explore the feasibility of developing immunosensors that combine antibodies for specific recognition with its Fluorogen Activating Peptide technology.
FAP is exclusively licensed by Sharp Edge. The technology was invented by the firm’s co-founders Alan Waggoner and Marcel Bruchez, both professors at Carnegie Mellon University.
Scott Sneddon, president and CEO of Sharp Edge and principal investigator on the grant, said that in the current state of technology, each biosensor recognizes only very specific molecules. As a result, each sensor needs to be designed from the ground up, a costly and time-consuming process. Sharp Edge aims to develop biosensors that can recognize numerous molecules with its new antibody-FAP technology.
You can read more about Sharp Edge and the grant on GenomeWeb Daily News (free subscription required).